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Objectives. We attempted to demonstrate that simultaneous
dipyridamole administration and maximal subjective exercise in
patients who are unable to achieve a good exercise level can
improve the diagnostic efficacy of technetium-99m methoxy isobu-
tyl isonitrile (99mTc-MIBI) myocardial single-photon emisson
computed tomography (SPECT).
Background. The results of myocardial perfusion scintigraphy
are unsatisfactory if the level of exercise achieved by the patient is
insufficient. The use of dipyridamole with maximal subjective
stress testing has been shown to improve the quality of the
thallium-201 myocardial perfusion images, but there are no
studies demonstrating that this combination improves the diag-
nostic accuracy of myocardial perfusion SPECT.
Methods. Two hundred thirty-one consecutive patients, without
a previous myocardial infarction, were classified into three
groups: group 1, 91 patients with an adequate exercise test; group
2, 68 patients with an inadequate exercise test; group 3, 72
patients with an inadequate exercise test who then received
intravenous dipyridamole (0.56 mg/kg body weight over 4 min)
simultaneously with exercise.
Results. Results for sensitivity (89%) and negative predictive
value (83%) in group 3 were significantly better than those in
group 2 (71% [p 5 0.03] and 56% [p 5 0.002], respectively) and
not significantly different from those in group 1. The polar maps
of 20 patients studied with and without dipyridamole at the same
exercise level revealed a significantly greater extent of ischemia in
each territory and in a global assessment (19 1 20% vs. 8 1 11%,
p < 0.0001) when dypiridamole was administered during physical
exercise.
Conclusions. Intravenous dipyridamole administration during
exercise testing is advisable in all patients who are unable to
achieve an adequate exercise level. This approach permits physi-
cians to avoid missing ergometric information while optimizing
myocardial SPECT results.
(J Am Coll Cardiol 1997;29:531–6)
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The administration of intravenous dipyridamole during perfu-
sion scintigraphy has been carried out since 1978 (1–4) with
good results in patients who are unable to perform a conven-
tional exercise test (5). Some investigators (6–9) have sug-
gested that the use of isometric exercise in association with
dipyridamole administration would improve test results. Per-
formance of dynamic exercise after dipyridamole administra-
tion has also been reported (10–17) to improve test results;
however, this approach implies giving dipyridamole to all
patients before they perform the exercise test.
In everyday practice, the clinician wants the information
provided by the exercise test itself when assessing the severity
of coronary artery disease (18). For this reason maximal
subjective stress testing is encouraged in most cases. However,
if the patient’s exercise level is insufficient, the yield of
perfusion scintigraphy is suboptimal (19–23). In many cases, it
is not possible to foresee which patients will achieve a high
enough heart rate and an appropriate peak O2 consumption
for an adequate test. Therefore, on the basis of promising
results with thallium-201 (201Tl) planar scintigraphy (24), we
designed a prospective protocol using technetium-99m me-
thoxy isobutyl isonitrile (99mTc-MIBI) myocardial single-
photon emission computed tomography (SPECT). In this
protocol we administered intravenous dipyridamole during
exercise to patients who, after the start of exercise testing, are
unable to achieve either 80% of the predicted peak heart rate
for their age or a peak O2 consumption .5 metabolic equiv-
alents (METs), or both.
The use of dipyridamole (25) or adenosine (26) in combi-
nation with a maximal subjective stress test has improved the
quality of the 201Tl myocardial perfusion images by providing a
better heart/background ratio and reducing the noncardiac
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side effects of these drugs. However, there are no studies
demonstrating that this combination improves the diagnostic
accuracy of myocardial perfusion SPECT.
The aim of the present study was to demonstrate that the
diagnostic value of 99mTc-MIBI SPECT performed in associ-
ation with simultaneous intravenous dipyridamole injection
during exercise is higher than that obtained with exercise
testing alone when physical performance is inadequate.
Methods
Study patients. We studied 231 consecutive patients free
from previous myocardial infarction who 1) had undergone
myocardial 99mTc-MIBI SPECT between October 1992 and
March 1995, and 2) had undergone coronary angiography
within 3 months of the SPECT study. During the SPECT study
period, 1,300 patients were evaluated with 99mTc-MIBI SPECT
in our institution. We excluded 1,069 of these patients because
1) coronary angiography was not available (n 5 650) or had
been performed .3 months before or after SPECT (n 5 48);
or 2) the patient had had a previous myocardial infarction (n5
209), had undergone myocardial revascularization (n5 119) or
had valvular heart disease (n 5 19), cardiomyopathy (n 5 12)
or left bundle branch block (n 5 12).
One hundred nine (47%) of the 231 included patients were
studied for diagnostic purposes because results of a previously
performed conventional stress test were inconclusive. In 35
(32%) of these 109 patients, peak heart rate had been insuffi-
cient, in 34 (31%) the results of stress electrocardiography
were indeterminate and in the remaining 40 (37%) coronary
artery disease was suspected clinically despite negative results
in an exercise electrocardiogram (ECG).
In 122 (53%) of the 231 included patients the diagnosis of
coronary artery disease was previously obtained by coronary
angiography, and 99mTc-MIBI SPECT was performed in prog-
nostic purposes. In 83 (68%) of the 122, SPECT was ordered
to localize ischemia; in the remaining 39 (32%) it was ordered
for assessment of the functional effect of an angiographically
demonstrated coronary stenosis that was of doubtful severity.
Ninety-five (78%) of these 122 patients had stable angina and
27 (22%) underwent SPECT during their hospital stay$3 days
after stabilization of unstable angina.
Since October 1992 it has been routine practice in our
laboratory to administer intravenous dipyridamole to all pa-
tients who do not achieve a peak heart rate 80% of that
predicted for age and .5 METs during exercise testing.
Dipyridamole is injected while exercise is continued, as de-
scribed later.
According to these criteria the study patients were classified
in three groups:Group 1 (adequate exercise test) comprised 91
patients who had a peak heart rate $80% of predicted value
for their age (220 beats/min 2 age) or who manifested ST
segment depression $1 mm or angina during the test. Group 2
(inadequate exercise test) comprised 68 patients who had a
peak heart rate ,80% of the predicted value, O2 consumption
.5 METs, no ST segment depression $1 mm and no angina.
Group 3 (inadequate exercise test plus dipyridamole during
exercise) comprised 72 patients with a peak heart rate ,80%
of the predicted value, O2 consumption ,5 METs and no ST
segment depression $1 mm or angina who received intrave-
nous dipyridamole during exercise.
Exercise test. All patients performed a symptom-limited
exercise test on a bicycle ergometer, with an initial load of
50 W and successive 25-W increments every 3 min until
exhaustion, symptoms or .2-mm ST segment depression de-
veloped.
An exercise test result was considered positive when the
patient had angina or $1-mm horizontal or downsloping ST
segment depression 0.08 s after the J point. ST segment
depression between 0.5 and 1 mm was considered indetermi-
nate.
Dipyridamole. Patients whose peak heart rate was ,80%
of the predicted value and whose oxygen consumption was
,5 METs (group 3) received intravenous dipyridamole
(0.14 mg/kg body weight per min for 4 min) while they
continued to exercise at the maximal tolerated load until 2 min
after the end of dipyridamole administration. When the first
level of exercise was not optimally tolerated by the patient
(50 W for a 70-kg adult represents an O2 consumption of
4.3 METs) the administration of dipyridamole was indicated.
Fifteen percent of patients needed lowering the maximal load
so as to complete dipyridamole administration. Administration
of the drug was interrupted if angina or $1-mm ST segment
depression developed.
To compare the extent of ischemia in polar maps in 20
patients with proved coronary artery disease (the last 9 patients
from group 2 and the last 11 from group 3), we submitted these
patients to two SPECT studies performed with and without
dipyridamole 1 week apart, at the same level of exercise.
99mTc-MIBI SPECT. All patients received an intravenous
dose of 99mTc-MIBI (15 mCi) 30 to 60 s before the end of
exercise. The stress and rest studies were carried out on
separate days, with an interval of $24 h; the same dose was
used for both studies. Images were acquired 1 h after admin-
istration of the radiopharmaceutical by using an Elscint SP4
scintillation camera with a high resolution collimator and a
semicircular orbit starting at a 308 right anterior oblique
position and with detection being carried out every 38. Recon-
struction was performed (Butterworth filter, order 5, section
frequency 0.4), and short-axis, horizontal long-axis and vertical
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long-axis sections were obtained according to current recom-
mendations (27) (Fig. 1).
Myocardial uptake was assessed by consensus of three
experienced observers who were unaware of the results of
coronary angiography. Thirteen segments were evaluated:
anterobasal, midanterior, anteroapical, septal-basal, midseptal,
septal-apical, inferobasal, midinferior, inferoapical, lateral-
basal, midlateral, lateral-apical and apical. In each of these
segments, uptake was assessed as normal, equivocal, mild,
moderate or severe defect (similar to the background uptake)
(28).
A SPECT study was considered positive only when a mild,
moderate or severe defect was present in stress images in at
least two of the three axes or in three consecutive tomographic
sections on the same axis of the stress images, with normal
uptake at rest.
In the 20 patients who underwent two SPECT studies, one
with and one without simultaneous dipyridamole administra-
tion, the extent of ischemia was quantified in the polar maps
(29). Following a methodology of our own, we established four
regions: anteroseptal, apical, inferior and lateral (Fig. 2). We
quantified the polar image of ischemia (using the difference
between the polar rest and polar exercise images and between
the polar rest and polar exercise plus dipyridamole images),
with a 10% cutoff value. In the polar image of ischemia all
pixels with values .10% are displayed in red. The extent of
ischemia is calculated as the percent rate of ischemia in the
interest area with pixel values .10% as compared with the
overall value of the area of each of the four regions. The
overall rate of ischemia is calculated from the four areas
weighted for their surface.
Cardiac catheterization. All patients underwent cardiac
catheterization. The procedure included left ventriculography
and coronary angiography, performed with the usual Seldinger
technique within 3 months of myocardial SPECT. Coronary
stenoses .50%, as established by the consensus of two experts
after visual examination, were considered significant.
Statistical analysis. The sensitivity, specificity, global
value, positive predictive value and negative predictive value
and their 95% confidence intervals were calculated for groups
1, 2 and 3. The chi-square test was used to compare results
between these groups. p # 0.05 was accepted as the level of
statistical significance.
In the 20 patients who underwent two SPECT studies (with
and without dipyridamole at the same exercise level), the
extent of ischemia (global and for each territory) in the polar
maps without and with dipyridamole was compared by using
the Student t test for paired data.
Results
Cardiac catheterization. The prevalence of coronary artery
disease in the study group was 65%. Eighty-two (35%) of the
231 patients in groups 1, 2 and 3 had angiographically normal
coronary arteries; of the remaining 149 patients, 46 had
one-vessel disease, 50 had two-vessel disease and 53 had
three-vessel disease. One hundred twenty-five had stenosis of
the left anterior descending coronary artery, 97 of the right
coronary artery and 83 of the left circumflex coronary artery
(Table 1).
All 20 patients (mean age 6 SD 58 6 8 years, 35% women)
with two SPECT studies (one with and one without dipyrida-
mole at the same exercise level) had coronary artery disease.
Six patients had .50% stenosis in one vessel, 3 in two vessels
and 11 in three vessels. The left anterior descending coronary
artery was involved in 15 patients, the right coronary artery in
16 and the left circumflex coronary artery in 14.
Exercise test and dipyridamole. Table 1 shows the clinical
characteristics, the purpose of the exercise test (diagnostic or
prognostic evaluation), test results and the treatment that
patients in the three groups were receiving when the test was
performed.
Angina developed after dipyridamole administration in 23
percent of the patients in group 3. These patients were given
Figure 1. Myocardial single-photon emission computed tomograms
from a patient after a submaximal exercise test (E), after a submaximal
exercise test plus dipyridamole (E 1 D) and at rest (R). The severity
of the inferior defect and its anteroseptal and apical extension are
clearly greater in E 1 D. hla 5 horizontal long axis; sa 5 short axis;
vla 5 vertical long axis.
Figure 2. Same patient. Polar maps after exercise (E), after exercise
plus dipyridamole (E 1 D) and at rest (R). At bottom, the extent of
ischemia is shown in red and clearly appears greater in the inferior (i,
33% vs. 11%), anteroseptal (as, 36% vs. 7%) and apical (a, 100% vs.
40%) territories after exercise test plus dipyridamole than after
exercise alone. See Methods. l 5 lateral.
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intravenous theophylline (125 to 250 mg), and the symptoms
were controlled in all. Headache after dipyridamole adminis-
tration was spontaneously reported by 8% of patients.
Table 2 shows the results of the two exercise tests in the 20
patients who underwent two SPECT studies (one with and one
without dipyridamole at the same exercise level).
Myocardial SPECT. The sensitivity, specificity, global
value and positive and negative predictive values of myocardial
SPECT in the three patient groups, with their 95% confidence
intervals, are shown in Table 3.
The results for sensitivity, global value and negative predic-
tive value in group 1 (adequate exercise test) were significantly
better (p 5 0.003, p 5 0.002 and p 5 0.002, respectively) than
those in group 2 (inadequate exercise test).
The results for sensitivity and negative predictive value in
group 3 (inadequate exercise test plus dipyridamole with
exercise) were significantly better (p 5 0.03 and p 5 0.02,
respectively) than in group 2 (inadequate exercise test) al-
though the patients in group 2 had a higher level of O2
consumption (6.1 6 1.2 vs. 3.9 6 1.3 METs, p , 0.0001).
The extent of ischemia in the polar maps from the exercise
tests with and without simultaneous dipyridamole in the 20
patients in whom two tests were performed is shown in Table
2. The extent of ischemia, in each territory and in all territories
considered as a whole, was significantly greater when dipyrid-
amole was administered in addition to physical exercise (Fig. 1
and 2).
Discussion
The good results obtained with perfusion scintigraphy by
using intravenous dipyridamole in patients unable to exercise
(1–4) and those obtained when exercise was undertaken after
the administration of dipyridamole at rest (10–16) prompted
us to design a protocol in which dipyridamole is administered
after the start of exercise testing in patients who prove unable
to achieve sufficient peak heart rate and oxygen consumption.
This protocol both permits assessment of the patient’s func-
tional capacity and avoids administering the drug to all pa-
tients.
Inadequate exercise test. A high proportion of patients
who undergo perfusion scintigraphy do not achieve a high
enough peak heart rate to confidently rule out coronary artery
disease if the test result is negative. In many instances the
diagnosis has already been made—for example, in patients
receiving antianginal drugs who undergo exercise perfusion
scintigraphy for prognostic purposes. The diagnostic efficacy of
perfusion scintigraphy with 201Tl (17–21) and radionuclide
Table 1. Clinical Characteristics and Results of Exercise Testing and







Age (yr) 57 6 9 56 6 10 61 6 9
Women 31% 22% 49%*
Aim of SPECT





Beta-blockers 36%† 65% 42%‡
Nitrates 36% 50% 60%
Calcium channel blockers 42% 60% 44%
Triple therapy 18% 21% 28%
Exercise test
Duration (min) 7.3 6 2.6 8 6 2.6 7.6 6 2.4
Watts 87.8 6 28 92.3 6 27 43 6 26§
METs 6.2 6 1.2 6.1 6 1.2 3.9 6 1.3\
Peak HR (beats/min) 130 6 23\ 106 6 18¶ 97 6 20#
% predicted HR 80 6 14%** 63 6 9% 61 6 12
SBP (mm Hg) 176 6 26 170 6 26†† 157 6 25#
HR 3 SBP 230 6 60** 181 6 45‡‡ 154 6 48
Angina 34% 0 23%
ST2 .1 mm 39% 0 28%
Cardiac catheterization
EF 62 6 11 64 6 10 64 6 9
Normal coronary arteries 34 (37%) 20 (29%) 28 (39%)
CAD
1-vessel 10 (11%)§§ 22 (32%) 14 (19%)\ \
2-vessel 25 (28%) 12 (18%) 13 (18%)
3-vessel 22 (24%) 14 (21%) 17 (24%)
LAD 50 (55%) 39 (57%) 36 (50%)
LCx 34 (37%) 22 (32%) 27 (37%)
RCA 43 (47%) 26 (38%) 28 (39%)
*p 5 0.003 versus groups 1 and 2. †p 5 0.0004 versus group 2. ‡p 5 0.006
versus group 2. §p , 0.0001 versus groups 1 and 2. \p , 0.0001 versus group 2.
¶p 5 0.01 versus group 3. #p , 0.0001 versus group 1. **p , 0.0001 versus
groups 2 and 3. ††p 5 0.003 versus group 3. ‡‡p , 0.001 versus group 3. §§p 5
0.0003 versus group 2. \ \p 5 0.004 versus group 1. Data are expressed as mean
value 6 SD or number (%) of patients. CAD 5 coronary artery disease; EF 5
ejection fraction; Group 1 5 patients with an adequate exercise test; Group 2 5
patients with an inadequate exercise test; Group 35 patients with an inadequate
exercise test plus dipyridamole with exercise; HR 5 heart rate; LAD 5 left
anterior descending coronary artery; LCx 5 left circumflex coronary artery;
METs 5 metabolic equivalents; RCA 5 right coronary artery; SBP 5 systolic
blood pressure; ST2 5 ST segment depression.
Table 2. Results of the Exercise Test and Extent of Ischemia (polar








Duration (min) 6.9 6 1.7 7 6 1.7 NS
Watts 78.1 6 27 78.1 6 27 NS
METs 5.6 6 1.5 5.6 6 1.5 NS
Peak HR (beats/min) 107 6 14 106 6 15 NS
% predicted HR 67 6 8% 65 6 9% NS
SBP (mm Hg) 170 6 23 168 6 23 NS
HR 3 SBP 181 6 60 178 6 58 NS
Extent of ischemia
Anteroseptal 6 6 8% 15 6 15% 0.003
Inferior 10 6 12% 18 6 18% 0.003
Lateral 7 6 8% 20 6 19% 0.006
Apical 10 6 15% 21 6 29% 0.02
Global 8 6 11% 19 6 20% , 0.0001
Data are expressed as mean value 6 SD. Abbreviations as in Table 1.
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ventriculography (30,31) has been shown to be suboptimal in
patients who have a low peak heart rate or are receiving
beta-blocker therapy, or both.
The sensitivity of 99mTc-MIBI SPECT was high in patients
who had peak O2 consumption values .5 METS and a peak
heart rate 80% of predicted value for age in this series and in
others (23) that used the same methods and interpretation
criteria. Therefore, we decided to establish a protocol for
administering dipyridamole during exercise in patients who did
not meet the criteria for adequate heart rate and O2 consump-
tion.
The present results confirm that the sensitivity of myocar-
dial SPECT is reduced in patients with an inadequate exercise
test (peak heart rate ,80% of predicted value for age in the
absence of symptoms or ischemic response in the exercise
ECG). About 70% of the patients with false negative results
were receiving beta-blocker therapy. As other investigators
(18,19,21) have suggested, this factor is clinically important,
and our findings highlight the need to withdraw such medica-
tion when the test is carried out for diagnostic purposes.
Inadequate exercise test plus dipyridamole. Our study
confirms the hypothesis that, with the administration of dipyr-
idamole simultaneously with physical exercise, the diagnostic
yield of myocardial SPECT can be significantly improved
without loss of the important prognostic data provided by a
maximal subjective exercise test.
With the simultaneous dipyridamole/exercise test, sensitiv-
ity improved from 71% in group 2 to 89% in group 3 (p5 0.03)
and the negative predictive value from 56% to 83%, respec-
tively (p 5 0.002), even though peak O2 consumption was
lower in group 3 (Table 1) because one criterion for adminis-
tering dipyridamole was the patient’s inability to exercise to
.5 METs. The only differences between the two groups were
the greater prevalence of one-vessel disease in group 2 with
respect to group 3 (32% vs. 19%, p 5 0.004) and the greater
proportion of women in group 3 with respect to group 2 (49%
vs. 22%, p 5 0.003). This finding might help to explain the
lower O2 consumption in group 3. In 15% of patients from
group 3, maximal load had to be reduced to complete dipyr-
idamole administration. In .90% of these patients, who had
coronary artery disease, 99mTc-MIBI SPECT showed ischemia;
therefore, we think that their inclusion does not distort the
results.
In addition, as shown in 20 patients who underwent exercise
SPECT studies both with and without dipyridamole, the extent
of ischemia as quantified in the polar maps was significantly
higher at the same levels of heart rate and METs when
dipyridamole was administered during exercise.
Pathophysiologic effects of dipyridamole plus exercise.
The vasodilation induced by dipyridamole, which may be up to
two or three times greater than that induced by exercise, accounts
for the greater flow to normally perfused areas than that to areas
in which perfusion is reduced. This phenomenon results in a more
reduced relative uptake of the radionuclide in the areas withmore
severe fixed stenoses. Exercise-induced hypoperfusion is always
accompanied by myocardial ischemia (“absolute hypoperfu-
sion”); this is not the case with dipyridamole-induced hypoperfu-
sion (“relative hypoperfusion”). Therefore, in most patients the
addition of dipyridamole infusion to exercise leads to maximal
vasodilation in combination with the effects of exercise, such as an
increase in heart rate, mean arterial pressure and contractility.
In addition, as other investigators (13,14,32) have shown,
the use of dipyridamole in combination with physical exercise
improves cardiac image quality because the myocardial
activity/background activity ratio is increased. The combined
protocol also attenuates the secondary effects of dipyridamole
which, in the absence of contraindications such as bronchial
asthma and unstable coronary artery disease, are rare, even
when this drug is given at rest (33,34).
Of the last 1,000 patients studied with 99mTc-MIBI SPECT
in our hospital, 13% could not perform any kind of dynamic
exercise and were tested pharmacologically. Only 23% had a
peak heart rate .80% of predicted value for age, and 40%
could not reach a peak heart rate of 80% of predicted value but
experienced angina, had ischemic ECG changes or O2 con-
sumption .5 METs. The remaining patients (24%) did not
exercise to peak heart rate of 80% of predicted value or
5 METs and did not have angina or ischemic ECG changes.
We believe that our results indicate that systematic dipyrida-
mole administration during exercise testing is warranted in
these patients. Dipyridamole, unlike adenosine or dobutamine,
can be directly administered intravenously in a short time
period and without a perfusion pump, which allows perfor-
mance of exercise testing during its administration. Thus, its
use permits physicians to obtain the clinical and ECG infor-
mation derived from a maximal subjective exercise test while
optimizing the results of myocardial SPECT.
We are grateful to Dr. Gaieta` Permanyer-Miralda for revision of the manuscript.













Group 1 (n 5 91) 93% (83%–98%)* 94% (80%–99%) 93% (86%–97%)† 96% (87%–100%) 89% (74%–97%)†
Group 2 (n 5 68) 71% (56%–83%) 90% (68%–89%) 76% (65%–86%) 94% (81%–99%) 56% (38%–74%)
Group 3 (n 5 72) 89% (75%–96%)‡ 86% (67%–96%) 87% (78%–94%) 91% (78%–97%) 83% (64%–99%)†
*p 5 0.003 versus group 2. †p 5 0.002 versus group 2. ‡p 5 0.03 versus group 2. CI 5 confidence interval.
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